hotspot -WSS

hotspot

author：hotspot 2025-09-30 17:28:28 - browse：39995

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Group behind ProMed defends move to subscription

focus

WSS

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Late stage cancers on the rise after pandemic delayed screenings

Alnylam reports growth in sales of rare disease treatments

FDA scientists endorse Pfizer/BioNTech Covid

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Wikipedia

hotspot

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Allen Institute goes after foundational questions, CEO Costa says

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Duchenne breakthrough therapy leaves behind pioneering families

Personalized medicine goes far beyond genetics

Medical records are filled with copy

Group behind ProMed defends move to subscription

How to save PrEP access — and even expand it

Medicare slashes safety net hospital payments by nearly $1 billion

hotspot

Biotech startup Celsius cuts 75% of staff ahead of first trial start

H.R. 3 is the wrong path to lower drug costs

Late stage cancers on the rise after pandemic delayed screenings

FDA early review: GLP

Profiling embryos to choose those with higher IQs is almost a reality

Medicare Advantage overpayments discussion gets experts fired up

focus

focus

focus

entertainment